Initial Feasibility Study of a New Transcatheter Mitral Prosthesis

Sorajja, Paul; Moat, Neil; Badhwar, Vinay; Walters, D.; Paone, Gaetano; Bethea, Brian; Bae, Richard; Dahle, Gry; Mumtaz, Mubashir; Grayburn, Paul A.; Kapadia, Samir; Babaliaros, Vasilis; Guerrero, Mayra; Satler, Lowell F.; Thourani, Vinod H.; Bedogni, Francesco; Rizik, David G.; Denti, Paolo; Dumonteil, Nicolas; Modine, Thomas; Sinhal, Ajay; Chuang, Michael L; Popma, Jeffrey J.; Blanke, Philipp; Leipsic, Jonathon; Muller, David W.M.

doi:10.1016/j.jacc.2018.12.066

Cited by 178 publications

(153 citation statements)

References 27 publications

Supporting

Mentioning

142

Contrasting

Unclassified

Order By: Relevance

“…[4][5][6] However, mechanical interference to valve closure was not identified as a factor in the publication by Vaturi et al and does not explain the increase in tricuspid regurgitation associated with temporary epicardial ventricular pacing. 7 Our recent experience during a mitral valve replacement is consistent with the findings by Vaturi et al…”

Section: Ventricular Pacingàinduced Tricuspid Regurgitation After Carsupporting

confidence: 92%

“…The discovery of a mitral leaflet cleft in a nonsurgical patient, may guide the interventional cardiology team to consider other minimally invasive percutaneous approaches such as transcatheter mitral valve replacement. 7,8 Using this strategy may have prevented the poor outcomes reported by Kam et al As MR treatment with the MitraClip increases globally, anesthesiologists should be aware of the effect of a mitral cleft on the success of this procedure.…”

mentioning

confidence: 99%

See 1 more Smart Citation

The Role of Nitric Oxide in Preventing Cardiopulmonary Bypass-associated Acute Kidney Injury

Lama

Zapol

2020

Journal of Cardiothoracic and Vascular Anesthesia

View full text Add to dashboard Cite

Section: Ventricular Pacingàinduced Tricuspid Regurgitation After Carsupporting

confidence: 92%

mentioning

confidence: 99%

The Role of Nitric Oxide in Preventing Cardiopulmonary Bypass-associated Acute Kidney Injury

Lama

Zapol

2020

Journal of Cardiothoracic and Vascular Anesthesia

View full text Add to dashboard Cite

“…The studies included patients at very high surgical risk and both devices were implanted transapically The 30-day mortality rate was 14% with the Intrepid device and 6% in the Tendyne study (26% at 1 year). However, it is important to notice that the complete correction of significant MR was constant in both studies [28,29,41]. Following these favorable results, the first trials aiming at comparing TMVR with to open surgery are already underway.…”

Section: Transcatheter Mitral Valve Replacementmentioning

confidence: 92%

“…Furthermore, TMVR carries risks [44]. Although less frequent with THVs dedicated to the mitral valve (< 1%), left ventricle outflow tract obstruction (LVOTO) has been reported in 1/8 patients when aortic THVs devices were used for TMVR [28][29][30]45]. LVOTO is defined by an increase of 10 mmHg or more of the transaortic gradient [46] and associated with higher mortality [43,[47][48][49].…”

Section: Transcatheter Mitral Valve Replacementmentioning

confidence: 99%

Advances in transcatheter mitral and tricuspid therapies

Overtchouk

Piazza

Granada

et al. 2020

BMC Cardiovasc Disord

Self Cite

View full text Add to dashboard Cite

Background: While rheumatic mitral stenosis has been effectively treated percutaneously for more than 20 years, mitral and tricuspid regurgitation treatment appear as a contemporary unmet need. The advent of transcatheter therapies offer new treatment options to often elderly and frail patients at high risk for open surgery. We aimed at providing an updated review of fast-growing domain of transcatheter mitral and tricuspid technology. Main body: We reviewed the existing literature on mitral and tricuspid transcatheter therapies. Mitraclip is becoming an established therapy for secondary mitral regurgitation in selected patients with disproportionately severe regurgitation associated with moderate left ventricle dysfunction. Evidence is less convincing for primary mitral regurgitation. Transcatheter mitral valve replacement is a promising emerging alternative to transcatheter repair, for secondary as well as primary mitral regurgitation. But further development is needed to improve delivery. Transcatheter tricuspid intervention arrives late after similar technologies have been developed for aortic and mitral valves and is currently at its infancy. This is likely due in part to previously under-recognized impact of tricuspid regurgitation on patient outcomes. Edge-to-edge repair is the most advanced transcatheter solution in development. Data on tricuspid annuloplasty and replacement is limited, and more research is warranted. Conclusion: The future appears bright for transcatheter mitral therapies, albeit their place in clinical practice is yet to be clearly defined. Tricuspid transcatheter therapies might address the unmet need of tricuspid regurgitation treatment.

show abstract

“…0.43; P<.001) when subvalvular pathology was addressed with papillary muscle approximation and muscle slings, and left ventricular reverse remodeling (as assessed by left ventricular end-diastolic volume diameter) were improved (mean diameter of 3.6 mm; P <.001). 7 The challenge for clinicians assessing patients with IMR is how best to assess proportionate and disproportional physiology (degree of IMR as an index of left ventricular end-diastolic volume), as well as asymmetric anatomies, in a highly heterogeneous patient population. The first goal is to distinguish patients who will benefit from a mitral valve intervention from those who will not.…”

mentioning

confidence: 99%